Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Islet Sciences, Inc.
RALEIGH, N.C., June 12, 2014 /PRNewswire/ -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the treatment and diagnosis of metabolic disease, announced today it will present three peer-reviewed posters relating to its differentiated sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate, at the 74th American Diabetes Association (ADA) Scientific Sessions at the Moscone Center in San Francisco, June 13-17.
Two of the posters describe positive Phase 2b clinical efficacy and safety results for remogliflozin etabonate in treating patients with type 2 diabetes. The third poster highlights the best-in-class potential of Islet's novel, bi-phasic formulation of remogliflozin etabonate.
The posters will be available for viewing in Hall D on Sunday, June 15, from 7:30am to 6:30pm Pacific Time, as part of the "Clinical Therapeutics/New Technology – Oral Agents" session. The individual posters are summarized below:
Title: Efficacy and Safety of Once Daily Remogliflozin for the Treatment of Type 2 Diabetes Mellitus
Authors: William O. Wilkison, PhD4; Andy P. Sykes, BSc. Hons.1; Lata Kler, PhD1; Gail L. Kemp, MSc1; Robert Dobbins, MD, PhD2; Robin O'Connor-Semmes, PhD2; Susan Walker4; Steve R. Almond, MMATH3
Title: Efficacy and Safety of Twice Daily Remogliflozin for the Treatment of Type 2 Diabetes Mellitus?
Authors: William O. Wilkison, PhD4; Andy P. Sykes, BSc. Hons.1; Lata Kler, PhD1; Jamie D. Lorimer (BSc. Hons.)1; Robin O'Connor-Semmes, PhD2; Robert Dobbins, MD, PhD2; David J. Dorey (MMATH)3; Susan Walker4?
Title: Novel Formulation of Remogliflozin Etabonate to Optimize Efficacy and Reduce Side Effects Associated with SGLT2 Inhibition
Authors: William O. Wilkison, PhD4; Susan Walker5; James Green4; Bentley Cheatham5
1Clinical Development, Cardiovascular and Metabolic Medicine Development Center, GlaxoSmithKline, Uxbridge, UK; 2Center for Metabolic Disease, GlaxoSmithKline, RTP, NC, USA; 3Clinical Statistics, GlaxoSmithKline, Mississauga, Canada; 4Islet Sciences, Inc., Raleigh, NC, USA; 5BHV Pharma, Research Triangle Park, NC, USA
About Islet Sciences
Islet Sciences, Inc., a biopharmaceutical company based in Raleigh, NC, is developing new medicines and technologies for the treatment and diagnosis of metabolic disease. On March 13, 2014, the Company announced the execution of a binding letter of intent to acquire BHV Pharma. The combined pipeline includes remogliflozin etabonate for the treatment of type II diabetes and NASH, a cell-based transplantation therapy for insulin-dependent diabetes; first-in-class immune-modulating small molecule IL-12 inhibitors targeting beta-cell preservation, and a PCR-based molecular diagnostic measuring beta-cell loss for the diagnosis of type 1 diabetes or onset of insulin dependent type 2 diabetes. For more information, please visit http://www.isletsciences.com.
This press release contains forward-looking statements. Forward-looking statements for Islet Sciences, Inc. reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science, Inc.'s reports filed with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of the Company's control.
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
email@example.com; (212) 375-2664
Amy Wheeler (Media)
firstname.lastname@example.org; (646) 362-5750
©2012 PR Newswire. All Rights Reserved.